https://www.marketscreener.com/quote/stock/PROMIS-NEUROSCIENCES-INC-120794341/news/Promis-Neurosciences-Inc-Doses-First-Subjects-in-Phase-1A-Clinical-Trial-of-PMN310-to-Treat-Alzheim-45397693/?utm_source=telegram&utm_medium=social&utm_campaign=share